Publications by authors named "Marie Coude"
Article Synopsis
- The ASXL1 gene is often mutated in blood cancers, particularly the c.1934dupG mutation, which is linked to worse patient outcomes, highlighting the need for better detection methods.
- Researchers developed a new assay called "PCR-Fluo-ASXL1-FA" that rapidly and cost-effectively detects the c.1934dupG mutation and other nearby insertions/deletions, in contrast to less sensitive methods like direct sequencing.
- Their study showed that this new approach is highly effective and should be used alongside next-generation sequencing (NGS) for comprehensive detection of ASXL1 mutations in myeloid malignancies.
[Chronic lymphocytic leukemia with t(14 ;18) and trisomy 12: a case report].
Ann Biol Clin (Paris)
August 2018
Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm defined by the presence of at least 5×10 G/L monoclonal B lymphocytes in the peripheral blood. It is the most common type of leukemia in adult patients from Western countries. CLL is characterized by a gradual accumulation of small, longliving, immunologically dysfunctional, morphologically mature-appearing B-lymphocytes in blood, bone marrow and lymphoid tissues.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluated the impact of NPM1-mutated minimal residual disease (MRD) on young adult patients with acute myeloid leukemia (AML) to see if it could help predict the benefits of stem cell transplantation.
- Among 152 patients analyzed after induction therapy, those with less than a 4-log reduction in MRD had a significantly higher chance of relapse and shorter overall survival.
- The findings suggest that early NPM1m MRD evaluation is a crucial prognostic tool and can guide decisions regarding the use of allogeneic stem cell transplantation in patients with unfavorable AML.
Prognosis of Philadelphia-positive (Ph(+)) acute lymphoblastic leukemia (ALL) in the elderly has improved during the imatinib era. We investigated dasatinib, another potent tyrosine kinase inhibitor, in combination with low-intensity chemotherapy. Patients older than age 55 years were included in the European Working Group on Adult ALL (EWALL) study number 01 for Ph(+) ALL (EWALL-PH-01 international study) and were treated with dasatinib 140 mg/day (100 mg/day over 70 years) with intrathecal chemotherapy, vincristine, and dexamethasone during induction.
View Article and Find Full Text PDFA methylenetetrahydrofolate reductase polymorphism (677 C/T mutation) was recently implicated in the etiology of Down syndrome. We studied a cohort of 85 women carrying fetuses with Down syndrome and found no difference in the frequencies of the three groups of subjects (C/C, C/T, T/T) between Down syndrome mothers and controls.
View Article and Find Full Text PDF